REG - IXICO plc - Collaboration with Microsoft

IXICOAnnouncement

15/03/2021 07:05

RNS Number : 1822S
  
IXICO plc
  
15 March 2021
  
 

IXICO plc
("IXICO" or the "Company")
 
Collaboration with Microsoft to support business scale up with global pharma 
 
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces a collaboration with Microsoft to develop its AI data analytics platform for the global pharmaceutical industry. Combining IXICO's portfolio of AI data analytics and scientific expertise in neurological diseases with Microsoft's cloud-based AI infrastructure, will provide a significant enabler for IXICO's delivery of clinical trial analytics solutions, at scale, to the pharmaceutical industry.
 
As part of the collaboration, the two companies will work together to deliver IXICO's AI solutions into global clinical trials for neurological diseases such as Alzheimer's disease and Huntington's disease by enhancing IXICO's large-scale data processing capabilities. These capabilities will set the foundation for an expanded range of differentiated and proprietary AI driven services, assisting IXICO's customers in their efforts to address significant unmet medical needs.
 
IXICO's remote access business model has supported significant growth in recent years and has proven to be an important differentiator in minimising disruption to clinical trials in the COVID-19 pandemic business environment. As the Company continues to scale in the highly regulated clinical trials environment, its cloud-based analytics platform is aimed at supporting decentralised clinical trial designs and the ability to collect and analyse greater volumes and types of therapeutic specific patient data, improving clinical insights available within neurological drug development.
 
Giulio Cerroni, Chief Executive Officer at IXICO, commented: "The partnership with Microsoft ensures we remain at the forefront of data analytics required by our global pharmaceutical clients, to provide new and valuable insights to reduce both the high cost of drug development and the time to market for urgently needed drugs across a wide range of neurological diseases. We are excited to work with Microsoft on our clinical trial data platform, as well as AI analytics framework, as we look to scale our business and increase our value to both current and prospective clients."
 
Laura Robinson, Director Health and Life Sciences at Microsoft UK, said: "Microsoft is working with companies in the life science sector to develop capabilities and maximise the positive impact of data and AI. IXICO and Microsoft are both focused on using technology to deliver better outcomes in this critical area."
 
For further information please contact:
 




IXICO plc


+44 (0)20 3763 7498




Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer


 




 


 




Cenkos Securities PLC (Nominated adviser and sole broker)


+44 (0)20 7397 8900




Giles Balleny / Max Gould (Corporate Finance)


 




Michael F Johnson / Russell Kerr (Sales)


 




 


 




Walbrook PR Ltd


+44 (0)20 7933 8780




Paul McManus / Lianne Cawthorne / Alice Woodings


IXICO@walbrookpr.com




 


 



 
 
 
 
 
 



 
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
 
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
AGRGPUAUWUPGGGW